Kelly applauds Medicare's new coverage of GLP-1 medications to help American seniors lead healthier, more fulfilling lives
WASHINGTON, D.C. -- Today, U.S. Rep. Mike Kelly (R-PA) applauded news from the Centers for Medicare and Medicaid Services (CMS) announcing eligible Medicare beneficiaries may now get certain GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge. The new CMS initiative is designed to expand access to innovative treatments and test the impacts of increased access to GLP-1 drugs for weight management on the Medicare program
Kelly leads theTreat and Reduce Obesity Act (TROA)in the U.S. House of Representatives. This bipartisan legislation aims to combat the obesity crisis in the United States by expanding coverage of new health care specialists and chronic weight management medications for Medicare recipients.
"This latest news from CMS provides American seniors with an affordable and accessible option to live healthier lives," said Rep. Kelly, who serves as a member of the Ways & Means Subcommittee on Health and also as a member of the Congressional Diabetes Caucus. "I want to applaud CMS Administrator Dr. Mehmet Oz and the Trump administration for establishing this critical pathway for these life-changing medications."
Kelly's legislation has 82 co-sponsors in the House.
Through the Medicare GLP-1 Bridge, eligible individuals enrolled in Medicare Part D prescription drug coverage can obtain certain GLP-1 medications to lose weight or maintain weight reduction at a predictable and affordable cost of $50 per month. The initiative will remain available through December 31, 2027, and reflects CMS’ continued focus on improving access to innovative treatments that support better long-term health outcomes.